國家衛生研究院 NHRI:Item 3990099045/9790
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 954572      線上人數 : 729
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9790


    題名: Effects of arsenic trioxide on the imatinib sensitivity of CD34+cells and c-Kit expression of CD34+/CD38-cells in K562 chronic myelocytic leukemia
    作者: Yeh, CT;Yeh, CF;Yao, CJ;Chuang, SE;Lai, GM
    貢獻者: National Institute of Cancer Research
    摘要: Imatinib is clinically effective in treating chronic myelocytic leukemia (CML) patients, but the imatinib resistant cells often caused the relapses and resulted in the failure of treatment. Agents against these imatinib resistant cells are of great importance for CML therapy. As the drug resistance and relapses of tumor were thought to be closely associated with cancer stem cells, we thus try to investigate if the effects of imatinib on the resistant or stem cell population in CML could be enhanced by arsenic trioxide, an effective remedy for acute myelocytic leukemia. It is reported that the Philadelphia chromosome-positive (Ph+), CD34+ cells from chronic phase CML patients were found to be resistant to imatinib, and the primitive Ph+ stem cells that have been described in the chronic phase of CML are CD34+/CD38-. Remarkably, a recent report showed that Ph+, CD34+/CD38+ progenitor cells from chronic phase CML patients are capable of self-renewal and engraftment into NOD-SCID mice. We thus identified and sorted these two populations (CD34+/CD38- and CD34+/CD38+) of cells from human Ph+ K562 CML cells and study the effects of imatinib and arsenic trioxide on their cell survival and expression of c-Kit, the receptor for stem cells factor, which is required for CML hematopoiesis. The results from flow cytometric detection showed that the proportion of CD34+CD38- and CD34+CD38+ cells within K562 cells were 0.87 and 4.74 %, respectively. The c-Kit was highly expressed in CD34+/CD38- cells but almost not detected in CD34+/CD38+ cells. Both arsenic trioxide and imatinib could effectively reduced the highly expressed c-Kit in CD34+/CD38- cells accompanied with significant decrease in cell viability, and appeared to have additive effects when combined imatinib with arsenic trioxide. Intriguingly, the CD34+/CD38+ cells were more resistant to both imatinib and Arsenic trioxide than CD34+/CD38- cells, and the enhancement effect of Arsenic trioxide on imatinib-exerted inhibition was more significant in this population of cells. Our results indicated that the CD34+/CD38+ cells should be regarded as more life-threatened population to CML patients subjected to imatinib treatment and combining imatinib in conjunction with arsenic trioxide may provide beneficial effects on elimination of these two populations of cells in CML patients.
    日期: 2009-05
    關聯: Cancer Research. 2009 May;69:Abstract number 1078.
    Link to: http://cancerres.aacrjournals.org/content/69/9_Supplement/1078
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0008-5472&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000209702603283
    顯示於類別:[賴基銘(2004-2008)] 會議論文/會議摘要
    [莊雙恩] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000209702603283.pdf16KbAdobe PDF383檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋